A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Immunoglobulin A Nephropathy (IgAN) diagnosis established on kidney biopsy - stable and maximum allowed or tolerated RASI (ACEI and/or ARB) dose for ≥ 3 months prior to starting the study - if receiving SGLT2I, DEARA, MRA or ERA must be on a stable and maximum allowed or tolerated dose for ≥ 3 months prior to starting the study - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- diagnosis of rapid progressive glomerulonephritis - clinically significant renal disease other than IgAN - uncontrolled diabetes mellitus with glycosylated hemoglobin (HbA1c) > 8.5% - history of kidney transplant or planned kidney transplant - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Conditions:
Kidney, Prostate & Urinary
Keywords:
Clinics and Surgery Center (CSC), iga Nephropathy, igan, Lupus Nephritis, Immunoglobulin A Nephropathy

More Information

Description: To evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria in adult participants with IgAN
Study Contact: Sahar Koubar - skoubar@umn.edu
Principal Investigator: Sahar Koubar
Phase: PHASE3
IRB Number: STUDY00021814